FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589675737> ?p ?o ?g. }

• W2589675737 abstract "Abstract Acute (a)GVHD is a major cause of morbidity and mortality after UD or mismatched related (MRD) donor stem cell transplantation (HSCT). The nucleoside analog pentostatin (pentos) is a potent inhibitor of the enzyme adenosine deaminase that induces lymphocyte depletion, with low risk of myelosuppression. We have investigated the addition of pentos to tacrolimus (tacro) and MTX as GVHD prophylaxis. Methods: This was an adaptive randomized, dose finding study that took into account toxicity and efficacy in a Bayesian adaptive design. Probability of assignment to the control group was fixed at 20%. Probability of assignment to the 4 dose groups was based on the probability that an arm’s success rate was greater than the control’s. Probabilities were recalculated after each observed patient outcome. Recipients of UD and MRD were eligible; all analysis is done by intention to treat. Success was patient being alive, engrafted, in complete remission (CR), without GVHD at study completion(100 days post HSCT). Grade III-IV aGVHD defined failure at any time, while gd. I-II did not constitute failure if absent on day 100. The study was designed to have a false positive rate of 0.05 and a power of 0.7 to detect a dose that had a 60% success rate for low-risk patients (HLA matched, in CR) and 45% for high-risk pts (mismatched, not in CR). High-resolution typing was prospectively available for 95% of donor-recipient pairs (HLA-A, B, C, DRB1 and DQB1 loci). Treatment plan: tacro from day-2; MTX 5 mg/m2 on days +1, +3, +6; day+11 was given only to controls. Pentos was given on days +8, +15, +22 and +30, in 4 ‘arms’: 0.5, 1, 1.5 and 2 mg/m2. Results: 147 pts, median age 49 yrs (18–72) were enrolled from 2001 to 2007. Diagnosis were AML/MDS (n=105), ALL(n=17), CML (n=18) and NHL (n=7); 48% of the pts were not in CR. Conditioning regimens (with ATG in 92% of the cases) were busulfan based (n=104), melphalan based(n=26), BEAM(n= 2), and CyTBI (n=15); 75% were ablative and 25%, reduced intensity. Stem cell source: bone marrow(n=120) and peripheral blood(n=27). Donors: UD(n=140) and MRD (n=7). Proportion of pts with donor-recipient HLA mismatches (HLA A, B, C, DRB1, DQB1) was 27%, 60%, 38%, 21% and 30%, respectively for the 5 study arms; median age was similar. 90% of the intended pentos doses were delivered. Time to engraftment was unafected. Incidence of toxicities (control vs study arms): renal(gd I-III) 34% vs 36%; TTP/HUS 6% vs 6%; early relapse 9% vs 5%; engraftment failure 3% vs 5.5%; delayed engraftment (>21 days): 6% vs 5%. Extensive cGVHD rate (control vs 1.5 mg/m2) was 52% vs 38%. Relapse rates are comparable. Conclusions: aGVHD rate may be reduced with pentostatin 1.5 mg/m2. A multicenter controlled study is planned in order to confirm these findings. Pentostatin dose control group n=37 0.5 mg/m² n=10 1 mg/m² n=29 1.5 mg/m² n=61 2 mg/m² n=10 gd II-IV aGVHD 57% 44% 40% 33% 50% gd III-IV aGVHD 20% 33% 18% 10% 10% Skin only aGVHD 45% 25% 50% 63% 67% Hepatic aGVHD 17% 50% 14% 2% 0 gd III-IV aGVHD n pts with <10/10 HLA match 1 in 9 2 in 5 5 in 11 0 in 11 0 in 3 CMV reactivation 63% 30% 48% 49% 50% Fungal infection 14% 10% 30% 16% 20% Not evaluable (n) 2 1 1 5 0" @default.
• W2589675737 created "2017-03-03" @default.
• W2589675737 creator A5004417292 @default.
• W2589675737 creator A5012676022 @default.
• W2589675737 creator A5015342719 @default.
• W2589675737 creator A5016475819 @default.
• W2589675737 creator A5034104852 @default.
• W2589675737 creator A5034264716 @default.
• W2589675737 creator A5036817347 @default.
• W2589675737 creator A5040975741 @default.
• W2589675737 creator A5048913229 @default.
• W2589675737 creator A5049589636 @default.
• W2589675737 creator A5050962913 @default.
• W2589675737 creator A5055885795 @default.
• W2589675737 creator A5055885925 @default.
• W2589675737 creator A5065661042 @default.
• W2589675737 creator A5066894053 @default.
• W2589675737 creator A5070096873 @default.
• W2589675737 creator A5071526808 @default.
• W2589675737 creator A5076320058 @default.
• W2589675737 creator A5083279961 @default.
• W2589675737 creator A5087389826 @default.
• W2589675737 date "2007-11-16" @default.
• W2589675737 modified "2023-10-15" @default.
• W2589675737 title "Prophylaxis of Graft-Versus-Host Disease (GVHD) with Pentostatin, Tacrolimus, and “Mini”-Methotrexate (MTX): A Phase I/II Controlled, Randomized Study in Unrelated Donor (UD) Transplantation." @default.
• W2589675737 doi "https://doi.org/10.1182/blood.v110.11.40.40" @default.
• W2589675737 hasPublicationYear "2007" @default.
• W2589675737 type Work @default.
• W2589675737 sameAs 2589675737 @default.
• W2589675737 citedByCount "0" @default.
• W2589675737 crossrefType "journal-article" @default.
• W2589675737 hasAuthorship W2589675737A5004417292 @default.
• W2589675737 hasAuthorship W2589675737A5012676022 @default.
• W2589675737 hasAuthorship W2589675737A5015342719 @default.
• W2589675737 hasAuthorship W2589675737A5016475819 @default.
• W2589675737 hasAuthorship W2589675737A5034104852 @default.
• W2589675737 hasAuthorship W2589675737A5034264716 @default.
• W2589675737 hasAuthorship W2589675737A5036817347 @default.
• W2589675737 hasAuthorship W2589675737A5040975741 @default.
• W2589675737 hasAuthorship W2589675737A5048913229 @default.
• W2589675737 hasAuthorship W2589675737A5049589636 @default.
• W2589675737 hasAuthorship W2589675737A5050962913 @default.
• W2589675737 hasAuthorship W2589675737A5055885795 @default.
• W2589675737 hasAuthorship W2589675737A5055885925 @default.
• W2589675737 hasAuthorship W2589675737A5065661042 @default.
• W2589675737 hasAuthorship W2589675737A5066894053 @default.
• W2589675737 hasAuthorship W2589675737A5070096873 @default.
• W2589675737 hasAuthorship W2589675737A5071526808 @default.
• W2589675737 hasAuthorship W2589675737A5076320058 @default.
• W2589675737 hasAuthorship W2589675737A5083279961 @default.
• W2589675737 hasAuthorship W2589675737A5087389826 @default.
• W2589675737 hasConcept C126322002 @default.
• W2589675737 hasConcept C141071460 @default.
• W2589675737 hasConcept C2775952470 @default.
• W2589675737 hasConcept C2779338263 @default.
• W2589675737 hasConcept C2779972918 @default.
• W2589675737 hasConcept C2780653079 @default.
• W2589675737 hasConcept C2781059491 @default.
• W2589675737 hasConcept C2909675724 @default.
• W2589675737 hasConcept C2911091166 @default.
• W2589675737 hasConcept C71924100 @default.
• W2589675737 hasConcept C90924648 @default.
• W2589675737 hasConceptScore W2589675737C126322002 @default.
• W2589675737 hasConceptScore W2589675737C141071460 @default.
• W2589675737 hasConceptScore W2589675737C2775952470 @default.
• W2589675737 hasConceptScore W2589675737C2779338263 @default.
• W2589675737 hasConceptScore W2589675737C2779972918 @default.
• W2589675737 hasConceptScore W2589675737C2780653079 @default.
• W2589675737 hasConceptScore W2589675737C2781059491 @default.
• W2589675737 hasConceptScore W2589675737C2909675724 @default.
• W2589675737 hasConceptScore W2589675737C2911091166 @default.
• W2589675737 hasConceptScore W2589675737C71924100 @default.
• W2589675737 hasConceptScore W2589675737C90924648 @default.
• W2589675737 hasLocation W25896757371 @default.
• W2589675737 hasOpenAccess W2589675737 @default.
• W2589675737 hasPrimaryLocation W25896757371 @default.
• W2589675737 hasRelatedWork W1978081888 @default.
• W2589675737 hasRelatedWork W2023977670 @default.
• W2589675737 hasRelatedWork W2097902267 @default.
• W2589675737 hasRelatedWork W2285404915 @default.
• W2589675737 hasRelatedWork W2439908272 @default.
• W2589675737 hasRelatedWork W2589675737 @default.
• W2589675737 hasRelatedWork W2884628875 @default.
• W2589675737 hasRelatedWork W2969487339 @default.
• W2589675737 hasRelatedWork W3000773779 @default.
• W2589675737 hasRelatedWork W3126729473 @default.
• W2589675737 isParatext "false" @default.
• W2589675737 isRetracted "false" @default.
• W2589675737 magId "2589675737" @default.
• W2589675737 workType "article" @default.